RH
Therapeutic Areas
BioMimetix JV Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BMX-001 | High-Grade Glioma | Phase 3 (preparing) |
Leadership Team at BioMimetix JV
JC
James Crapo, MD
CEO
DS
David S Silberstein, PhD
VP of R&D
SG
Shayne Gad, PhD
VP of Drug Safety, Regulatory Affairs
RO
Robert Ogden, CPA
CFO
SP
Sara Penchev
Director of Clinical Operations
JW
John Wetzel, PhD
Director, Chemistry, Manufacturing and Controls